id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-0862-0206,FDA,FDA-2021-N-0862,"TAB C-NSURE-ProposedRule-Final RE Memorandum - Nonprescription Drug Product With an Additional Condition for Nonprescription Use (Proposed Rule); Publication Date: June 28, 2022",Supporting & Related Material,Background Material,2023-01-20T05:00:00Z,2023,1,,,2023-01-20T20:02:50Z,,0,0,09000064855fd2fe
FDA-2021-N-0862-0203,FDA,FDA-2021-N-0862,"TAB B-2017-723-NSURERULE-TRACK CHANGE FROM ORIGINAL TO FINAL RE Memorandum - Nonprescription Drug Product With an Additional Condition for Nonprescription Use (Proposed Rule); Publication Date: June 28, 2022",Supporting & Related Material,Background Material,2023-01-20T05:00:00Z,2023,1,,,2023-01-20T20:02:31Z,,0,0,09000064855fd148
FDA-2021-N-0862-0201,FDA,FDA-2021-N-0862,"TAB A-2017-723-NSURE-PRIA RE Memorandum - Nonprescription Drug Product With an Additional Condition for Nonprescription Use (Proposed Rule); Publication Date: June 28, 2022",Supporting & Related Material,Background Material,2023-01-20T05:00:00Z,2023,1,,,2023-01-20T20:02:18Z,,0,0,09000064855fd2fb
FDA-2021-N-0862-0204,FDA,FDA-2021-N-0862,"TAB B-NSURE-PRIA-TRACK CHANGE FROM ORIGINAL TO FINAL RE Memorandum - Nonprescription Drug Product With an Additional Condition for Nonprescription Use (Proposed Rule); Publication Date: June 28, 2022",Supporting & Related Material,Background Material,2023-01-20T05:00:00Z,2023,1,,,2023-01-20T20:02:37Z,,0,0,09000064855fd149
FDA-2021-N-0862-0205,FDA,FDA-2021-N-0862,"TAB C-NSURE-PRIA-Final RE Memorandum - Nonprescription Drug Product With an Additional Condition for Nonprescription Use (Proposed Rule); Publication Date: June 28, 2022",Supporting & Related Material,Background Material,2023-01-20T05:00:00Z,2023,1,,,2023-01-20T20:02:44Z,,0,0,09000064855fd2fd
FDA-2021-N-0862-0200,FDA,FDA-2021-N-0862,"Memorandum - Nonprescription Drug Product With an Additional Condition for Nonprescription Use (Proposed Rule); Publication Date: June 28, 2022",Other,Memorandum,2023-01-20T05:00:00Z,2023,1,2023-01-20T05:00:00Z,,2023-01-20T20:01:00Z,,0,0,09000064855fd0c5
FDA-2021-N-0862-0202,FDA,FDA-2021-N-0862,"TAB A-2017-723-NSURERULE RE Memorandum - Nonprescription Drug Product With an Additional Condition for Nonprescription Use (Proposed Rule); Publication Date: June 28, 2022",Supporting & Related Material,Background Material,2023-01-20T05:00:00Z,2023,1,,,2023-01-20T20:02:25Z,,0,0,09000064855fd147